The nation of Zimbabwe has rejected a substantial US health deal valued at 367 million US dollars (£272m) spanning five years because of Washington's demand for confidential biological samples.
This move came to light following a government memo dated December was leaked, revealing that President Emmerson Mnangagwa felt the agreement was "lopsided".
An official representative later stated that the US was seeking genetic material for research and commercial purposes but was unwilling to share the benefits from any future vaccines.
"We must now begin the challenging and unfortunate task of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had provided over $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged further talks to reach a deal suitable to both sides so the nation's vital HIV treatment initiative can be sustained.
Wider Implications
Zimbabwe's decision comes after a similar case in Kenya, where a court suspended a similar health funding agreement after legal challenges were filed about the safety of citizens' medical information.
Since returning to office last year, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered aid for the US government, but Trump stated its spending was "wasteful" and his government was pursuing direct bilateral agreements to boost transparency and accountability.
As per reports, Sixteen nations in Africa have so far agreed to similar agreements, representing over $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership would have delivered significant advantages for the people of Zimbabwe, especially the 1.2 million currently receiving HIV treatment through American-funded initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to share its genetic material and health information over an extended period, without any corresponding assurance of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"Effectively, our country would supply the basic resources for medical research with no certainty that the end products would be accessible to our citizens should a future health crisis emerge."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its push of one-on-one deals were upending structures previously established via the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to deal with future global health emergencies.
"This mechanism is designed to ensure that when a country contributes its data, the benefits – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to create them."
The government's concerns over the US deal "are not meant as hostility towards the US," he added.
"We welcome ongoing dialogue with our American counterparts on how subsequent collaboration could be arranged in a way that respects the independence and dignity of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but urged that negotiations should continue given that a large portion of the nation's Aids initiatives relied on international support.
"In cases where specific concerns arise, including those involving data governance or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," the group commented.
This impasse highlights the complex tensions between receiving crucial foreign assistance and safeguarding local interests in an ever more interconnected world.